New Delhi, Jul 25 (PTI) Drug major Cipla Ltd on Friday reported a 10% rise in consolidated profit after tax (PAT) at ?1,298 crore for the quarter ended June 30, 2025, supported by strong sales growth across India, Europe, and Africa. The company had posted a PAT of ?1,178 crore in the same quarter last year.
Total income from operations rose to ?6,957 crore, up from ?6,694 crore a year ago, Cipla said in a statement.
Managing Director and Global CEO Umang Vohra said Cipla’s One-India business grew 6% year-on-year, with branded prescription therapies outpacing market growth and the trade generics business returning to a positive trajectory.
"Going ahead, the focus will be on growing our key markets, building flagship brands, investing in our future pipeline, and resolving regulatory issues," Vohra added.
Key highlights of Q1 FY26 performance:
India sales: ?3,070 crore, up 6% from ?2,898 crore YoY.
North America sales: ?1,933 crore, down 7% YoY.
Emerging markets & Europe: ?861 crore, up 11% from ?779 crore YoY.
Africa sales: ?871 crore, up 14% from ?766 crore YoY.
Cipla’s shares were trading 3.8% higher at ?1,543.80 on the BSE following the results.